SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

Bispecific antibodies and asymmetric Fc fusion proteins offer opportunities for important advances in therapeutics. Bivalent IgG depends upon in vivo dimerization of its heavy chains, mediated by homodimeric association of its C(H)3 domains. We have developed a heterodimeric Fc platform that supports the design of bispecific and asymmetric fusion proteins by devising strand-exchange engineered domain (SEED) C(H)3 heterodimers. These derivatives of human IgG and IgA C(H)3 domains create complementary human SEED C(H)3 heterodimers that are composed of alternating segments of human IgA and IgG C(H)3 sequences. The resulting pair of SEED C(H)3 domains preferentially associates to form heterodimers when expressed in mammalian cells. SEEDbody (Sb) fusion proteins consist of [IgG1 hinge]-C(H)2-[SEED C(H)3], that may be genetically linked to one or more fusion partners. This investigation reports on the generation of mono-Fab-Sb and Sb-IL2 monocytokine as models. They were expressed at high levels in NS/0 cells, purified on recombinant protein A resin and were well-behaved in solution. When administered intravenously to mice, Sb pharmacokinetics exhibited the long serum half-life extensions typical of comparable Fc-containing immunofusion and IgG1 controls.

• Publication year

  2010

• Venue

  Protein engineering, design & selection : PEDS

• Publication date

  2010-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1093/protein/gzp094PMID 20299542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

  2009cited by this paper
• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

  2008cited by this paper
• Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

  2007cited by this paper
• Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

  2007cited by this paper
• Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin

  2007cited by this paper
• Structure-guided SCHEMA recombination of distantly related beta-lactamases.

  2006cited by this paper
• Single Variable Domain-IgG Fusion

  2006cited by this paper
• Physically realistic homology models built with ROSETTA can be more accurate than their templates.

  2006cited by this paper
• Structure-guided SCHEMA recombination of distantly related β-lactamases

  2006cited by this paper
• T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.

  2005cited by this paper
• A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma

  2005cited by this paper
• A revival of bispecific antibodies.

  2004cited by this paper
• Bispecific antibody conjugates in therapeutics.

  2003cited by this paper
• Insights into IgA-mediated immune responses from the crystal structures of human FcαRI and its complex with IgA1-Fc

  2003influential reference
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma1

  2002cited by this paper
• Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

  2000cited by this paper
• High level expression and secretion of Fc-X fusion proteins in mammalian cells.

  1998cited by this paper
• Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.

  1998cited by this paper
• An efficient route to human bispecific IgG

  1998cited by this paper
• Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.

  1997cited by this paper
• Design and production of novel tetravalent bispecific antibodies

  1997cited by this paper
• Antibody binding sites.

  1996cited by this paper
• Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.

  1996cited by this paper
• 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

  1996cited by this paper
• High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

  1995cited by this paper
• Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

  1992cited by this paper
• Protein-protein recognition and the association of immunoglobulin constant domains.

  1990cited by this paper
• Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities

  1990cited by this paper
• High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

  1989cited by this paper
• Diverse organization of immunoglobulin VH gene loci in a primitive vertebrate.

  1988cited by this paper
• Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

  1987cited by this paper
• Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments.

  1985cited by this paper
• Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

  1985cited by this paper
• Hybrid hybridomas and the production of bi-specific monoclonal antibodies.

  1984cited by this paper
• Hybrid hybridomas and their use in immunohistochemistry

  1983cited by this paper
• Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

  1981cited by this paper

• The making of multispecific immunoglobulins – a clinical perspective

  2026cites this paper
• Emerging Role of Bispecific Antibodies in Precision Medicine, Cancer and Modern Therapeutics

  2026cites this paper
• Strategies for the Generation of Bispecific Antibodies

  2025cites this paper
• Trispecific SEED antibodies engineered for neutrophil-mediated cell killing

  2025cites this paper
• Taming interleukin‐12: Engineering of bispecific antibody‐based IL‐12 mimetics with biased agonism capacities

  2025cites this paper
• From discovery to the clinic: structural insights, engineering options, clinical, and ‘next wave’ applications of camelid-derived single-domain antibodies

  2025cites this paper
• Unlocking the potential of bispecific ADCs for targeted cancer therapy

  2024cites this paper
• Exploiting the Fc base of IgG antibodies to create functional nanoparticle conjugates

  2024cites this paper
• Macrophage-engaging peptidic bispecific antibodies (pBsAbs) for immunotherapy via a facile bioconjugation strategy

  2024cites this paper
• Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.

  2024cites this paper
• Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows

  2024cites this paper
• Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

  2024cites this paper
• An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

  2024cites this paper
• Design and engineering of bispecific antibodies: insights and practical considerations

  2024cites this paper
• Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment.

  2024cites this paper
• Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET

  2024cites this paper
• Bispecific antibody drug conjugates: Making 1+1>2

  2024cites this paper
• End-To-End Automated Intact Protein Mass Spectrometry for High-Throughput Screening and Characterization of Bispecific and Multispecific Antibodies

  2024cites this paper
• On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality

  2024cites this paper
• Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

  2024cites this paper
• Bispecific antibodies: advancing precision oncology.

  2024cites this paper
• Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

  2024cites this paper
• Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors

  2023cites this paper
• Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics

  2023cites this paper
• Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

  2023cites this paper
• Cattle-derived knob paratopes grafted onto peripheral loops of the IgG1 Fc region enable the generation of a novel symmetric bispecific antibody format

  2023cites this paper
• AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study

  2023cites this paper
• Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

  2023cites this paper
• A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

  2023cites this paper
• Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli

  2023cites this paper
• Tuning the Assembly of Bispecific Antibodies by Playing on Differential Polypeptide Chain Molar Ratios

  2023cites this paper
• Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy

  2023cites this paper
• Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition

  2023cites this paper
• Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A

  2023cites this paper
• Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.

  2023cites this paper
• A novel brick for bispecific antibody construction

  2023cites this paper
• NKp46‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats

  2023cites this paper
• Generation of bispecific antibodies by structure-guided redesign of IgG constant regions

  2023cites this paper
• Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics

  2022cites this paper
• A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies

  2022cites this paper
• Multifunctional NK Cell–Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release

  2022cites this paper
• Opportunities and challenges of bi-specific antibodies.

  2022cites this paper
• The manufacturing considerations of bispecific antibodies

  2022cites this paper
• A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties

  2022cites this paper
• Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

  2022cites this paper
• Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection

  2022influential citation
• Leveraging light chain binding avidity for control of mispaired byproducts during production of asymmetric bispecific antibodies.

  2022cites this paper
• Characterization and monitoring of a novel light-heavy-light chain mispair in a therapeutic bispecific antibody.

  2021cites this paper
• Rational selection of building blocks for the assembly of bispecific antibodies

  2021cites this paper
• Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

  2021cites this paper
• Introduction to Antibody Engineering

  2021cites this paper
• Next generation Fc scaffold for multispecific antibodies

  2021cites this paper
• Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity

  2021cites this paper
• Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing

  2021cites this paper
• IgG-like bispecific antibody platforms with built-in purification-facilitating elements.

  2021cites this paper
• Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

  2021cites this paper
• A new approach to produce IgG4-like bispecific antibodies

  2021cites this paper
• Bispecific Antibodies: From Research to Clinical Application

  2021cites this paper
• Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

  2020cites this paper
• Bispecific Antibodies

  2020cites this paper
• Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening

  2020cites this paper
• Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents

  2020cites this paper
• Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.

  2020cites this paper
• Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific

  2020cites this paper
• Novel antibody-based therapeutic approaches for redirecting T cell effector functions towards tumors expressing CD248 (TEM1)

  2020cites this paper
• Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform

  2020cites this paper
• A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates.

  2020cites this paper
• Engineered Technologies and Bioanalysis of multispecific Antibody Formats

  2020cites this paper
• A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.

  2020cites this paper
• A Generic Procedure for the Isolation of pH- and Magnesium-Responsive Chicken scFvs for Downstream Purification of Human Antibodies

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Considerations for the Design of Antibody-Based Therapeutics.

  2020cites this paper
• Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.

  2020influential citation
• Intein mediated high throughput screening for bispecific antibodies

  2020cites this paper
• Biology drives the discovery of bispecific antibodies as innovative therapeutics.

  2020cites this paper
• Bispecific antibodies: a mechanistic review of the pipeline

  2019cites this paper
• A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.

  2019cites this paper
• A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities.

  2019cites this paper
• Acid pH promotes bispecific antibody formation by the redox procedure.

  2019cites this paper
• Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc

  2019cites this paper
• Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules

  2019cites this paper
• Single-Molecule 3D Images of “Hole-Hole” IgG1 Homodimers by Individual-Particle Electron Tomography

  2019cites this paper
• The research and development of bispecific antibodies

  2019cites this paper
• Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

  2019cites this paper
• Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma

  2019cites this paper
• A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

  2019cites this paper
• Design and Production of Bispecific Antibodies

  2019cites this paper
• Lawrence Berkeley National Laboratory Recent Work Title Single-Molecule 3 D Images of " Hole-Hole " IgG 1 Homodimers by Individual-Particle Electron Tomography

  2019cites this paper
• Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models

  2019cites this paper
• Isolation of highly selective IgNAR variable single-domains against a human therapeutic Fc scaffold and their application as tailor-made bioprocessing reagents.

  2019cites this paper
• Towards The Development of Biobetter Therapeutic Whole Antibodies

  2019cites this paper
• Therapeutic bispecific antibody formats: a patent applications review (1994-2017)

  2018cites this paper
• Bispecific antibodies: design, therapy, perspectives

  2018cites this paper
• Emerging trends in bispecific antibody and scaffold protein therapeutics

  2018cites this paper
• Bispecific and Biparatopic Antibody Drug Conjugates

  2018cites this paper
• Bispecific Antibodies: Formats and Areas of Application

  2018cites this paper
• Engineering IgG-Like Bispecific Antibodies—An Overview

  2018cites this paper
• Novel Technologies for Generation of Bispecific Constructs

  2018cites this paper
• Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds

  2018cites this paper